Program
vonoprazan
Also written as “TAK-438”, “Vonoprazan” and “Vonoprazan (Reference)”.
Its studies are mostly in Esophagitis · Stomach Ulcer · Gastroesophageal Reflux · Heartburn · Duodenal Ulcer, led by 5 companies.
Drug pageVonoprazan: every studyMany companies study it; this page follows only the 48 they lead. All 100 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takedaits history only | 310 open or running | phase 4since Feb 8, 2016 | Sep 16, 2011 | none ahead |
| Phathom Pharmaceuticalsits history only | 142 open or running | phase 3since Oct 10, 2019 | Oct 10, 2019 | Oct 20, 2027phase 3 · NCT07752407 |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Nov 14, 2021 | Nov 14, 2021 | none ahead |
| Hanlim Pharm. | 10 open or running | phase 1since Oct 14, 2024 | Oct 14, 2024 | none ahead |
| Humanis Saglık Anonim Sirketiits history only | 10 open or running | phase 1since Dec 9, 2025 | Dec 9, 2025 | none ahead |
Also a collaborator on its studies: Richmond Pharmacology.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hanlim Pharm. only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 14, 2024First study: phase 1 study in Stomach UlcerFirst studyNCT06642987 · 30 enrolled · Korea, Republic of
TargetBeta
“Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Esomeprazolerule | AstraZeneca | phase 4 | 129 |
| Rabeprazolerule | Eisai | phase 4 | 66 |
| Omeprazolerule | AstraZeneca | phase 4 | 56 |
| tegoprazanrule | HK inno.N | phase 4 | 48 |
| fexuprazanrule | Daewoong Pharmaceutical | phase 4 | 29 |
Studies
The one study Hanlim Pharm. leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06642987Stomach Ulcer · Korea, Republic of | 1 | Completed | Nov 3, 2023 | 30 |
How it is read
Names in the registry
- “TAK-438”, 32 entries
- “Vonoprazan”, 20 entries
- “Vonoprazan (Reference)”, 1 entry
- “Vonoprazan Tablets”, 1 entry
- “VOQUEZNA® Tablets”, 1 entry
Conditions, from the studies’ own filings
- Esophagitis, 9 studies
- Stomach Ulcer, 9 studies
- Gastroesophageal Reflux, 7 studies
- Heartburn, 3 studies
- Duodenal Ulcer, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.